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administrative cost database. Clinical validation of the al-
gorithm is warranted.
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OBJECTIVES: The total economic impact of type 2 diabe-
tes in Germany is widely unknown and underestimated
since its complications are often not taken into account.
The pan-European cost of illness study (CODE-2: Costs of
Diabetes in Europe, Type 2) aimed at measuring the total
cost of patients with type 2 diabetes including both costs
of management and complications.
METHODS: For Germany, a bottom-up, prevalence-
based design was used to collect data on resource utilisa-
tion of 809 patients with diabetes type 2 for the year 1998.
A representative random sample of 135 office-based physi-
cians (GPs and specialists) provided data using patients’
medical records in face-to-face interviews. For the extrapo-
lation on a population level, costs were weighted accord-
ing to prevalence data on complications derived from an
epidemiological pre-study. Data were analysed from a so-
cietal perspective.
RESULTS: Total direct medical costs per patient per year
were on average DM 7,012, ranging from DM 156 to DM
137,512. The main part of the costs (61%) was induced
by hospitalisations and long-term care. Observed costs per
treatment type were DM 5,890 for diet, DM 5,621 for
OAD and DM 9,799 for insulin-treated patients. The
analysis per complication status showed a range from DM
3,716 for patients without, and up to DM 13,283 for pa-
tients with both micro- and macrovascular complications.
Assuming a diabetes type 2 prevalence of 4.24%, the total
annual direct costs for the respective population were esti-
mated to be DM 24,388 million.
CONCLUSIONS: The data substantiate the enormous so-
cio-economic burden and that costs are much higher than
estimated in previous studies. Treatment costs of diabetes
show a broad variance. Costs increase with age and are
highly related to occurrence of complications and onset of
insulin treatment. Furthermore, the study highlights that
costs are directly related to the severity of the patient’s ill-
ness.
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OBJECTIVES: Underlying the success of multi-country
cost of illness studies are the methods used to identify, enu-
merate and value the resources that constitute the overall
costs of the disease being studied. The design objective of
the data collection instruments is to ensure consistency be-
tween countries and retrieval of all relevant data.
METHODS: The CODE-2* (Costs of Diabetes in Europe
type 2) study is a bottom-up, prevalence based cost of ill-
ness study conducted to evaluate the total burden of type 2
diabetes in 8 European countries. The objective of the
study was to fully identify all costs relating to the manage-
ment of the disease and its associated complications in ad-
dition to patient demographic and clinical parameters.
Data for over 7000 patients were collected retrospectively
over a 6-month period from a variety of sources including
patient interviews, medical records and registries. This re-
quired the design of common data collection tools that
could be used in all eight countries by over 600 practitio-
ners included in the study. Identification of core items of
resource utilisation and clinical assessments was done in
consultation with European and national advisory boards
consisting of health economists, clinicians and healthcare
researchers. A process of forward and back translation en-
sured the cultural and linguistic integrity of the eight lan-
guage versions used. Layout and instrument design were
developed by iteration between the central study coordi-
nating and country teams and assessed by mini-pilots. Fi-
nal field tests ensured acceptability and suitability for
study participants.
RESULTS: The resulting country specific practitioner and
patient data collection instruments were consistent in all
aspects for core resource utilisation items necessary for in-
ter-country comparison of the study results.
CONCLUSION: The instruments and development pro-
cess used for the CODE-2 study should serve as a model
for other multi-country cost of illness studies. *Registered
Trademark of SmithKline Beecham
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OBJECTIVES: To estimate for the United Kingdom (UK)
and France the first year diabetes-related costs of naive pa-
tients with type 2 diabetes initiated upon therapy with the
same oral hypoglycemic agent (Diamicron). In both the
UK and France, responsibility for the care of patients with
type 2 diabetes rests with general practitioner physicians.
METHODS: Patient records of consecutive naive patients
were collected from general practices (two in the UK, one in
France). Diabetes-related resource utilization and costs for
the first year post-initiation of oral therapy were analyzed.
This included medication, professional visits, hospital out-
patient visits, emergency visits, inpatient hospitalizations,
laboratory tests and procedures, and self-administered tests.
